Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1042-1046

  Bellino, Silvio ^a   Paradiso, Erika ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE;

ADULT; ARTICLE; BORDERLINE STATE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; INCREASED APPETITE; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STANDING; XEROSTOMIA;

EID: 33747187764     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0705     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for borderline patients. New York, NY: John Wiley & Sons; 1999
3. Livesley WJ. A practical approach to the treatment of patients with borderline personality disorder. Psychiatr Clin North Am 2000;23:211-232
4. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder. Washington, DC: American Psychiatric Association; 2001
5. Schulz SC. The promise of atypical antipsychotics for borderline disorders. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa
6. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy [case report]. J Nerv Ment Dis 1997;185:34g-349
7. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46:1429-1435
8. Hough DW. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder [letter]. J Clin Psychiatry 2001;62:296-297
9. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62:849-854
10. Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-109
11. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-244
12. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65:903-907
13. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005;162:1221-1224
14. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-405
15. Chengappa KN, Baker RW, Sirri C. The successful use of clozapine in ameliorating severe self-mutilating in a patient with borderline personality disorder. J Personal Disord 1995;9:76-82
16. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477-484
17. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-107
18. Swinton M. Clozapine in severe borderline personality. J Forensic Psychiatry 2001;12:580-591
19. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997;133:323-328
20. Hellewell JSE, Cameron Hands D, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range. Schizophr Res 1998;29:154
21. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine ("Seroquel") monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-291
22. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559
23. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003;4:42-44
24. Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63(suppl 13):32-38
25. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington DC: American Psychiatric Press; 1997
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
27. Ventura J, Green M, Shaner A, et al. Training and quality assurance with the Brief Psychiatric Rating Scale: "the drift busters." Int J Methods Psychiatr Res 1993;3:221
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
29. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
30. Goldman HH, Skodol AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-1156
31. Arntz A, van den Hoorn M, Cornells J, et al. Reliability and validity of the borderline personality disorder severity index. J Personal Disord 2003;17:45-59
32. Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep 1965;16:547-554
33. Barratt ES. Impulsiveness and aggression. In: Monahan J, Steadman HJ, eds. Violence and Mental Disorder: Developments in Risk Assessment. Chicago: University of Chicago Press; 1994:61-79
34. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 1995;51:768-774
35. Fossati A, Di Ceglie A, Acquarini E, et al. Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. J Clin Psychol 2001;57:815-828
36. Guy W. Dosage Record and Treatment Emergent Symptom scale (DOTES). In: ECDEU Assessment Manual for Psychopharmacology, Revised. Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:223-244
37. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005;28:163-168
38. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005;7:307-325